Ronald Segura, MD
Interventional Pain Medicine · Covington, LANPI 1467619254
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,675 of the $4,015 with a category attached, or 66.6%. 24 manufacturers reported payments, led by Relievant Medsystems, Inc. at 26.7% of the total. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 131 payments — averaging $30.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Relievant Medsystems, Inc.$1K
- Spinal Simplicity, LLC$1K
- Biotronik NRO, Inc.$404
- Boston Scientific$384
- AbbVie$228
- Sentynl Therapeutics, Inc.$146
- plus $762 from 18 others
What the payments were for
- Travel & lodging$1,32033%
- Food & beverage$2,67567%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Relievant Medsystems, Inc. | 9 | $1,072 |
| Spinal Simplicity, LLC | 17 | $1,020 |
| Biotronik NRO, Inc. | 9 | $404 |
| Boston Scientific | 18 | $384 |
| AbbVie(2 entities) | 15 | $228 |
| Sentynl Therapeutics, Inc. | 12 | $146 |
| Vertiflex, Inc. | 9 | $129 |
| Collegium Pharmaceutical, Inc. | 9 | $110 |
| Pfizer | 7 | $104 |
| Tersera Therapeutics LLC | 4 | $72 |
| Scilex Pharmaceuticals Inc. | 4 | $52 |
| Medtronic | 2 | $48 |
| Amgen | 3 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Biodelivery Sciences International, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Avanos Medical | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Painteq LLC | 1 | $13 |
| MDD US Operations, LLC | 1 | $12 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,942
- HA MINUTEMAN G3-R$701
- Prospera$133
- GENERAL PAIN MANAGEMENT$119
How this compares
$4,015 in reported general payments places this provider in the 40th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 350 | $249,160 |
| OxycontinOxycodone Hcl | 181 | $116,891 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 3,087 | $112,038 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,403 | $90,476 |
| Oxycodone Hcl | 3,438 | $86,150 |
| BelbucaBuprenorphine Hcl | 52 | $46,554 |
| Buprenorphine | 146 | $43,963 |
| Gabapentin | 2,700 | $42,148 |
| Morphine Sulfate ErMorphine Sulfate | 1,110 | $36,663 |
| BotoxOnabotulinumtoxina | 20 | $28,180 |
| Fentanyl | 137 | $22,553 |
| Pregabalin | 1,151 | $16,950 |
| Fentanyl Citrate | 11 | $16,319 |
| NucyntaTapentadol Hcl | 12 | $15,728 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $15,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta | $110 | $311,442414 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone | $21 | $50,277273 claims |
| AbbVieBotox | $228 | $28,18020 claims |
| PfizerLyrica | $104 | $8,49511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Covington
- Richard RobertsonCovington$6K
- Allan ParrCovington$5K
- Chad DomangueCovington$1K
- Donald RichardsonCovington$1K
- Lisa JaubertCovington$524
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.